IIIA期pN2非小细胞肺癌术后放疗选择:转移淋巴结数目的影响
该研究基于SEER数据库2004至2013年3373例IIIA期pN2非小细胞肺癌术后患者,比较术后放疗与观察对总生存和肺癌特异性生存的影响。多因素分析显示,阳性淋巴结数大于3枚的患者接受术后放疗与更好的生存相关,而阳性淋巴结数不超过3枚的患者未观察到生存获益。
要点
- IIIA期pN2患者中,阳性淋巴结数大于3枚者术后放疗与更好OS和LCSS相关。
- 阳性淋巴结数不超过3枚者,术后放疗未显示OS和LCSS获益。
- 术后放疗是阳性淋巴结数大于3枚患者生存的独立危险因素,而非不超过3枚者。
核心结论
- IIIA期pN2非小细胞肺癌中,阳性淋巴结数大于3枚的患者接受术后放疗较未接受者生存更好,而阳性淋巴结数不超过3枚的患者未观察到该获益。
研究设计与样本
- 基于SEER数据库识别2004至2013年接受肺叶切除或全肺切除的IIIA期pN2非小细胞肺癌患者3373例,比较术后放疗组与观察组。
主要发现
- 总生存和肺癌特异性生存均 favoring 术后放疗用于IIIA期pN2非小细胞肺癌患者。
- 多因素分析显示术后放疗和阳性淋巴结数不超过3枚均与更好的OS和LCSS独立相关。
- 生存分析中阳性淋巴结数大于3枚患者接受术后放疗后OS和LCSS均更好,而阳性淋巴结数不超过3枚组未再观察到OS和LCSS获益。
- 多因素分析显示术后放疗是阳性淋巴结数大于3枚患者生存的独立危险因素,而非阳性淋巴结数不超过3枚者。
临床怎么用
- 对于IIIA期pN2非小细胞肺癌术后患者,可依据阳性淋巴结数目考虑术后放疗决策,阳性淋巴结数大于3枚者可能从术后放疗中获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postoperative radiation (PORT) is an option for non-small cell lung cancer (NSCLC) patients with resectable stage IIIA pathological N2 status (pN2). For patients with PORT, this study aims to investigate the impact of the exact number of positive lymph nodes (LNs) on overall survival (OS) and lung cancer-specific survival (LCSS). METHODS: Within the Surveillance, Epidemiology, and End Results database, we identified 3373 patients with stage IIIA pathological N2 status (pN2) NSCLC who underwent a lobectomy or pneumonectomy from 2004 to 2013. OS and LCSS were compared among patients coded as receiving PORT or observation. The proportional hazards model was applied for investigation. RESULTS: OS and LCSS favored PORT for patients with stage IIIA (pN2) NSCLC. Multivariable analyses showed that PORT and the exact number of positive LNs (n ≤ 3) were independently associated with better OS and LCSS. Both better OS and LCSS emerged for positive LNs (n > 3) after the use of PORT in survival analyses, whereas the benefits of OS and LCSS were not observed anymore for positive LNs (n ≤ 3) group. More importantly, multivariable analyses showed that the use of PORT is an independent risk factor of survival for positive LNs (n > 3) but not for positive LNs (n ≤ 3). CONCLUSIONS: In Stage IIIA (pN2) NSCLC, the use of PORT demonstrated better survival results than no PORT for patients with positive LNs (n > 3), but not for patients with positive LNs (n ≤ 3).
引用
- Wang S, Ma Z, Yang X, et al. Choice of postoperative radiation for stage IIIA pathologic N2 non-small cell lung cancer: impact of metastatic lymph node number. Radiat Oncol. 2017. PMID: 29284511. doi:10.1186/s13014-017-0946-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。